CLDI — Calidi Biotherapeutics, Inc.

Is CLDI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Calidi Biotherapeutics, Inc. (CLDI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.60. The rating moved from Strong Oversold to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Calidi Biotherapeutics, Inc. (CLDI) is a small, early-stage biotech with limited public disclosures and little visible revenue. The company’s short-term outlook is driven by binary clinical and corporate events; absent clear near-term positive readouts or strategic partner news, the shares are exposed to dilution risk, low liquidity and sector rotation toward larger, defensive healthcare names. Key items to monitor are cash runway, upcoming clinical milestones, any EDGAR filings or partnership announcements, and broader biotech financing conditions. Upside would require positive data or meaningful non-dilutive financing; downside scenarios center on financing-driven dilution or negative trial/regulatory outcomes.

Key factors

  • Early-stage clinical/microcap profile with limited public financial disclosures and no recent EDGAR analysis available
  • Constrained liquidity and typical microcap volatility, increasing downside from adverse flows or news
  • High probability of near-term financing needs given typical cash burn in small biotechs; sector shows convertible-debt/dilution pressure
  • Few visible near-term commercial revenues; valuation driven primarily by binary clinical or partnership catalysts
  • Macro/sector flows currently favor large-cap pharma and defensive healthcare, which can sap investor interest in small biotechs
  • Potential positive catalysts include clinical data readouts, strategic partnerships or non-dilutive financing

Risks

  • Need for near-term capital leading to significant equity dilution or debt with onerous terms
  • Negative or failed clinical trial outcomes or regulatory setbacks for lead programs
  • Intense competition from larger pharmaceutical/biotech companies with deeper resources
  • Low trading liquidity and wide bid-ask spreads amplifying price moves on limited volume
  • Operational risks including manufacturing, trial enrollment delays, or CRO issues
  • Market-risk: rotation away from small-cap biotech or negative sector headlines could accelerate downside

See today's live rating, score and targets

Members see the live hourly rating for CLDI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.